Clinical Trial Update: Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of Eflornithine (DFMO) and Etoposide for relapsed/refractory Neuroblastoma; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Eflornithine (DFMO) (difluoromethylornithine)
• Etoposide (Etoposide)

Snippet

Sponsor: Giselle Sholler | Conditions: Neuroblastoma | Phase 2 | Status: RECRUITING